
News|Videos|November 17, 2023
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC
Author(s)Benjamin Solomon, MBBS, PhD, FRACP
Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
2
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
3
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
4
Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
5




















































